Advertisement

  • Loading metrics

Open Access

Peer-reviewed

Research Article

Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects

  • Glen B. Banks,

    Roles Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing – original draft, Writing – review & editing

    Affiliations Department of Neurology, University of Washington, Seattle, Washington, United States of America, Department of Medicine, University of Washington, Seattle, Washington, United States of America, Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington, United States of America

    ⨯
  • Jeffrey S. Chamberlain,

    Roles Conceptualization, Resources

    Affiliations Department of Neurology, University of Washington, Seattle, Washington, United States of America, Department of Medicine, University of Washington, Seattle, Washington, United States of America, Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington, United States of America, Department of BioChemistry, University of Washington, Seattle, Washington, United States of America

    ⨯
  • Guy L. Odom

    Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Supervision, Visualization, Writing – original draft, Writing – review & editing

    godom@uw.edu

    Affiliations Department of Neurology, University of Washington, Seattle, Washington, United States of America, Department of Medicine, University of Washington, Seattle, Washington, United States of America, Wellstone Muscular Dystrophy Specialized Research Center, University of Washington, Seattle, Washington, United States of America

    ⨯

Abstract

Gene therapy approaches for DMD using recombinant adeno-associated viral (rAAV) vectors to deliver miniaturized (or micro) dystrophin genes to striated muscles have shown significant progress. However, concerns remain about the potential for immune responses against dystrophin in some patients. Utrophin, a developmental paralogue of dystrophin, may provide a viable treatment option. Here we examine the functional capacity of an rAAV-mediated microutrophin (μUtrn) therapy in the mdx4cv mouse model of DMD. We found that rAAV-μUtrn led to improvement in dystrophic histopathology & mostly restored the architecture of the neuromuscular and myotendinous junctions. Physiological studies of tibialis anterior muscles indicated peak force maintenance, with partial improvement of specific force. A fundamental question for μUtrn therapeutics is not only can it replace critical functions of dystrophin, but whether full-length utrophin impacts the therapeutic efficacy of the smaller, highly expressed μUtrn. As such, we found that μUtrn significantly reduced the spacing of the costameric lattice relative to full-length utrophin. Further, immunostaining suggested the improvement in dystrophic pathophysiology was largely influenced by favored correction of fast 2b fibers. However, unlike μUtrn, μdystrophin (μDys) expression did not show this fiber type preference. Interestingly, μUtrn was better able to protect 2a and 2d fibers in mdx:utrn-/- mice than in mdx4cv mice where the endogenous full-length utrophin was most prevalent. Altogether, these data are consistent with the role of steric hindrance between full-length utrophin & μUtrn within the sarcolemma. Understanding the stoichiometry of this effect may be important for predicting clinical efficacy.

Author summary

Duchenne muscular dystrophy (DMD) is a severe muscle wasting disorder caused by mutations in the dystrophin gene. Utrophin is structurally similar to dystrophin and can potentially be utilized to prevent muscle necrosis in preclinical models of DMD. Consequently, utrophin-mediated therapies are a primary target for treating DMD, particularly as it may circumvent immune responses to dystrophin-mediated therapies. One promising therapeutic option is to utilize recombinant adeno-associated viral vectors (rAAV) to deliver a rationally designed miniaturized utrophin (μUtrn) to striated muscles to prevent necrosis. Here, we found that rAAV-μUtrn can profoundly prevent skeletal muscle necrosis in the mdx4cv mouse model of DMD. μUtrn was also able to replace many functions of dystrophin at the neuromuscular synapse and myotendinous junctions. However, we provide several lines of in vivo evidence that steric hindrance between μUtrn and the endogenous full-length utrophin on the sarcolemma impacts the longevity of the therapy in a muscle fiber-type selective manner. Understanding the stoichiometry of this effect may be important for predicting clinical efficacy.

Citation: Banks GB, Chamberlain JS, Odom GL (2020) Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. PLoS Genet 16(11): e1009179. https://doi.org/10.1371/journal.pgen.1009179

Editor: Gregory A. Cox, The Jackson Laboratory, UNITED STATES

Received: July 1, 2020; Accepted: October 6, 2020; Published: November 11, 2020

This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Data Availability: All relevant data are within the manuscript and its Supporting Information files.

Funding: GBB was supported by grants from the Muscular Dystrophy Association (MDA) and the American Heart Association. GLO was supported by a T32 National Research Service Award and by a grant from the muscular dystrophy association (MDA) USA. The studies were additionally supported by a NIH grant AR40864 (to JSC). AAV vectors were produced by the Viral Vector Core lab of the Seattle Wellstone Muscular Dystrophy Specialized research Center (NIH grant P50 AR065139) (www.mda.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

Duchenne muscular dystrophy (DMD) is a severe muscle wasting disorder caused by mutations in the dystrophin gene [1, 2]. Mechanically, dystrophin functions in muscle akin to a large molecular spring that connects the cytoskeleton via actin to the dystrophin-glycoprotein complex (DGC) within the sarcolemma [3–8]. As such, muscle membranes in DMD are highly susceptible to contraction-induced injury and hypoxic stress after mild exercise [9–17]. Furthermore, the neuromuscular junctions in the mdx mouse model of DMD fragment upon skeletal muscle necrosis, and have fewer and shallower postsynaptic folds than wild-type muscles [18–20]. The folding is also reduced at the myotendinous junctions, which is a prominent site for force transfer and injury in some DMD patients [21–26]. The dystrophin protein contains an N-terminal actin binding domain, a large central rod domain, a cysteine rich region critical for the association with β-dystroglycan[27], and a C-terminal domain [28, 29] (Fig 1A). The large central rod domain includes 24 spectrin-like repeats that interact with the membrane [30], F-actin [31], localize nNOS to the sarcolemma [32, 33], and guide peripheral microtubules [34]. The central rod domain also includes 4 hinge regions that contain high concentrations of proline residues [8]. As an X-linked disorder, DMD is potentially amenable to dystrophin replacement gene therapies [35, 36]. In fact, rational design of miniaturized dystrophins for gene therapy using rAAV has proven affective at mitigating the dystrophic pathophysiology in various mammalian models of DMD [29, 32, 37–41]. Clinical trials that utilize different forms of μDys have reported varied success at an early stage of treatment, but none are anticipated to fully restore normal muscle function[42]. One concern regarding DMD clinical therapeutic development is the possibility that dystrophin may be recognized by the immune system as a neo-antigen in some DMD patients [43–46]. As such, we are also interested in the therapeutic capacity of the dystrophin paralogue, utrophin [44, 47].

thumbnail
Download:
Fig 1. Domain structure of dystrophin, utrophin and μUtrn.

Shown is an illustration depicting the major functional domains of full-length, (427 kDa) dystrophin, (400 kDa) utrophin, and (130 kDa) microutrophin (μUtrn). Dystrophin contains two actin-binding domains [ABD1, which has 2 calponin-homology domains (CH), and ABD2), while the single ABD of utrophin is continuous through spectrin-like repeat 10. The central rod domain of dystrophin is composed of 24 spectrin-like triple-helical elements or repeats (R) while utrophin contains 22 repeats, both proteins carry 4 hinge (H) domains. Toward the carboxy-terminus a WW domain within hinge 4 together with a cysteine rich (CR) domain composed of 2 EF-hands, and a Zinc finger domain (ZZ), form a binding domain for beta-dystroglycan. The Carboxyl-terminal domain (C-term) provides binding sites for the syntrophins and dystrobrevins. Micro-utrophin lacks repeats 4–22 as well as the CT domain (Odom, 2010).

https://doi.org/10.1371/journal.pgen.1009179.g001

Utrophin is structurally similar to dystrophin in that it contains an N-terminal actin-binding domain, a large central rod domain containing 22 spectrin-like repeats with 4 hinges, a cysteine rich region and a C-terminal domain [28] (Fig 1). Despite the structural similarities, utrophin differs from dystrophin in a variety ways, such as having a single actin-binding domain that extends from the N-terminus through to spectrin-like repeat 10; in contrast dystrophin has a secondary actin binding domain (ABD2, Fig 1) [48]. Interestingly, utrophin also displays differing molecular contact responses to actin relative to dystrophin, affecting rotational dynamics, resulting in increased actin resilience [48, 49]. Indeed, it has been hypothesized that one continuous actin binding site may display less elasticity toward contractile responses via the actin-utrophin-sarcolemma linkage to muscle stretches relative to dystrophin[50]. Whether this could be exacerbated in vivo considering the structure of micro-utrophin(ΔR4-R21/ΔCT) (μUtrn), having a continuous ABD that constitutes for ~65% of the entire micro-protein, is not known. To this end, it has also been found that μUtrn is as effective in vitro at regulating actin dynamics as full-length dystrophin as determined by time-resolved phosphorescence anisotropy[51]. A further contrast from dystrophin in the central rod domain has been demonstrated downstream of the dystrophin ABD2, where utrophin lacks the binding domains associated with nNOS restoration to the sarcolemma or the ability to guide microtubules[34, 52]. Despite these differences, transgenic expression of full-length utrophin can prevent muscle necrosis in sedentary mdx mice, thus making it a promising candidate for treating DMD patients, independent of the type or placement of the dystrophin mutation [44, 53]. The μUtrn construct contains essential functional elements of the native utrophin, namely N-terminal actin-binding domain, four spectrin-like triple helices of the central rod domain (R1-R3 + R22), two hinges (H2 & H4), and the CR domain enabling binding to beta-dystroglycan[27](i.e. ΔR4-R21/ΔCT), enabling DGC assembly for localization at the sarcolemma [7, 9, 54–56]. Indeed, repeat administration of TAT-μUtrn has been shown to mitigate the pathophysiology of mdx and mdx:utrn-/- double knockout (dko) mice [57, 58]. Similarly, rAAV-mediated delivery of uUtrn prolongs the lifespan and mitigates the skeletal muscle dystrophic pathophysiology of dko mice [47] and in the canine model of DMD[46]. Although μUtrn therapy for dko mice clearly provided a benefit with improvement and stabilization of the histopathology with improved functional capacity, and lifespan extension; animals were not “cured” per se as a result of the treatment. Importantly, in a recent study utilizing rAAV9-mediated μUtrn delivery to severely affected D2/mdx mice, a demonstrated benefit of the cardiac phenotype was reported using cine-MRI for indices such as stroke volume and ejection fraction, providing the first evidence of a functional cardiac benefit with μUtrn upregulation [59].

A potential compounding issue with a μUtrn therapeutic for DMD is whether endogenous utrophin could influence the expression, localization, and inherent functional capacity of μUtrn, with utrophin being generally present at low levels on the sarcolemma and also highly concentrated within the neuromuscular and myotendinous junctions [60–62]. The design of μUtrn was based on the first generation μDys(ΔR4-R23/ΔCT) capable of being packaged within AAV, where the μDys cDNA contained the N-terminal actin binding domain, a small central rod domain containing hinges 1, 2, and 4, with four spectrin-like repeats, and the cysteine rich region [47, 63] (Fig 1A). Of note, μUtrn also includes a conserved polyproline site within hinge 2, that when present in μDys(ΔR4-R23/ΔCT), led to myotendinous strain injury, ringed myofiber formation, fragmentation of the neuromuscular synapses, and elongation of the synaptic folds in a subset of muscles in mdx mice [19, 26, 39]. Similar deleterious effects might be caused by the inclusion of hinge 2 in μUtrn. Therefore, in addition to histopathological and physiological assessment, this study was further aimed at evaluating neuromuscular and myotendinous junctions in mdx4cv mice treated with AAV-mediated delivery of μUtrn.

Results

Fig 1 shows the domain structure of the μUtrn(ΔR4-R21/ΔCT) protein used in this study as well as the structures of full-length dystrophin and utrophin [63]. The 1,160 residue, 130 kDa μUtrn has an analogous structure to a highly functional first-generation μDys(ΔR4-R23/ΔCT) we described previously [47, 63], currently being tested in phase 1/2 clinical trials (NCT03375164). Both micro-proteins carry 4 spectrin-like repeats in the central rod domain, but contain the entire N-terminal actin-binding and the cysteine-rich (CR) dystroglycan-binding domains, enabling essential binding to F-actin, beta-dystroglycan, and assembly of the dystrophin-glycoprotein complex (DGC) at the sarcolemma (except for nNOS) [7, 9, 52, 54–56, 64]. The μUtrn protein also lacks the C-terminal (CT) domain, which can be deleted from utrophin or dystrophin with minimal impact on function [47, 63, 65]. The absence of the CT domain also enables endogenous Utrn to be distinguished from μUtrn using antibodies that recognize the CT domain. Both proteins are detected with antibodies against the N-terminal domain of Utrophin A. In some studies we added a N-terminal flag epitope for exclusive detection of μUtrn. Expression vectors for μUtrn were prepared in rAAV6 as previously described [37, 47, 66].

Histopathlogy of mdx4cv muscles treated with μUtrn

Utrophin is expressed in new and maturing skeletal muscles during embryonic development in humans, and in mice this extends to ~2-weeks postnatal. As the muscle matures, utrophin expression is reduced and is ultimately replaced by dystrophin on the sarcolemma of normal muscles, but remains concentrated at the neuromuscular and myotendinous junctions. In the absence of dystrophin in DMD, utrophin appears to maintain this cadence where the expression is reduced as the muscle matures. However, without dystrophin expression to replace utrophin, the muscles become highly susceptible to contraction-induced injury. Muscle necrosis and the resulting inflammatory response activates resident satellite cells to regenerate myofibers leading to the re-establishment of utrophin at the sarcolemma of the maturing fibers. This cycle of utrophin expression continues for as long as the satellite cells are capable of replacing the lost muscle and leads to a patchwork of utrophin expression in the mdx muscles that are reflective of the stage of regeneration and maturation (Fig 2A). It is well known that slower muscle fiber types have higher levels of residual utrophin on the sarcolemma in DMD and are more resistant to the dystrophic pathophysiology[67–69]. To examine the effects of expressing human μUtrn in dystrophic mice, rAAV6-CMV-μUtrn (2x1010 vector genomes (vg) was injected into the right gastrocnemius and tibialis anterior (TA) muscles of 1 week old mdx4cv mice, with the sham-injected contralateral muscles as controls. At 3 months post-injection the tissues were harvested, and adjacent cryosections were immunostained with N-terminal utrophin antibodies to detect both μUtrn and endogenous full-length utrophin (FL-Utrn), and with C-terminal utrophin antibodies to exclusively detect FL-Utrn. Sections were also stained with hematoxylin and eosin to detect inflammatory pathology and centrally-nucleated myofibers, a hallmark of muscle regeneration (Fig 2A, panels 5, 6; S1 Fig).

thumbnail
Download:
Fig 2. μUtrn expression mitigates dystrophic pathology.

(A.) Adjacent sections of mdx4cv muscles and mdx4cv muscles directly injected with rAAV6-CK8-μUtrn. Scale bar = 50 μm. (B.) Western blot showing full length utrophin and μUtrn in untreated (left) and treated (right) gastrocnemius muscles (n = 4). GAPDH is the loading control. (C.) Quantitation of utrophin signal intensity from the Western blots. ***P < 0.001 compared to utrophin full-length in the treated muscles. (D.) Quantitation of full length utrophin and micro-utrophin mRNA by qRT-PCR. ***P < 0.001 compared to utrophin full-length in treated and untreated muscles.

https://doi.org/10.1371/journal.pgen.1009179.g002

Consistent with previous studies [70], upregulated FL-Utrn was detectable in most myofibers within the dystrophic environment of untreated mdx4cv mouse gastrocnemius muscles (Fig 2A, panels 1, 3). Approximately 76% of the myofibers in untreated mdx4cv gastrocnemius muscles exhibited central nuclei (a marker of muscle regeneration, S1A Fig) and extensive areas of mononuclear cell infiltrates (Fig 2A, panel 5). Intense N-terminal immunostaining of Utrn was observed in the rAAV6-CMV-μUtrn-treated gastrocnemius muscles. Only ~3% of the Utrn-positive myofibers in treated muscles displayed centrally-located nuclei (S1 Fig). Importantly, the muscle fibers expressing uUtrn also contained low levels of FL-Utrn as demonstrated by the antibody that recognizes the C-terminus of FL-Utrn and is absent in the uUtrn.

μUtrn-treated gastrocnemius muscles also displayed an improved morphological appearance and significantly fewer regenerating myofibers, as assessed by immunostaining for “developmental” (embryonic or neonatal) myosin heavy chain (18% positive myofibers compared with 67% for controls; (Fig 2A, panels 5 and 6; S1 Fig). This reduction in myofiber regeneration presumably accounts for the reduced full-length (FL) utrophin expression observed by both western analysis and immunostaining (Fig 2B and 2C), as regenerating myofibers have been shown to express elevated utrophin levels [71]. In contrast to the reduction in protein levels in treated mice, we found no difference in FL-Utrn mRNA levels between treated and untreated mdx4cv gastrocnemius muscles (Fig 2D). As anticipated, the mRNA levels of CMV-driven μUtrn were found to be much higher than the full-length transcripts in treated muscles (P < 0.001; Fig 2D). Expression of μUtrn in mdx4cv gastrocnemius muscles is thus sufficient to substantially ameliorate the dystrophic pathology.

Physiological performance of mdx4cv muscles treated with μUtrn

To assess the functional capacity of μUtrn to ameliorate physiological deficits in mdx4cv muscles, we analyzed contractile properties of the treated TA muscles in situ, followed by assessment of morphology and utrophin expression.

We examined several physiological parameters known to be altered in mdx4cv TA muscles: (1) Muscle Mass: As previously reported muscle mass increases significantly in mdx mice and this is thought to be partially responsible for maintaining peak force production of mdx muscles [72, 73]. We confirmed the mass increase of mdx4cv TA muscles, and found that μUtrn expression partially reduced this increase (Fig 3A). (2) Peak Force Production: The increased muscle mass maintains peak force production in mdx4cv mice at this age, and was also unchanged in limbs treated with uUtrn. (Fig 3B). (3) Specific Force Production: This parameter is typically reduced in mdx muscles [37, 73], and we found it to be reduced by about 35% in mdx4cv TA muscles; μUtrn-treatment restored about 60% of this deficit (P<0.05; Fig 3C). (4) Susceptibility to Eccentric Contraction-Induced Injury: Since mdx4cv muscles are known to be susceptible to contraction-induced injury [37, 73], we used an in situ strain protocol to determine whether μUtrn treatment would ameliorate this damage. When subjected to increased strain, peak tetanic force production of mdx4cv TA muscles decreased significantly compared to the smaller decrease in wild type TAs. In contrast, μUtrn-treated dystrophic muscles exhibited significant protection against this perturbation (Fig 3D), albeit to a degree notably less than in wild type muscles or in previous studies with micro-dystrophin ([26], & S3 Fig).

thumbnail
Download:
Fig 3. In situ physiological assessment of tibialis anterior muscles following vector treatment.

(A.) Mean +/- S.D. tibialis anterior muscle mass. (B.) Mean +/- S.D. peak tetanic force production. (C.) Mean +/- S.D. specific force production. (D.) Peak tetanic force production after increasing strain. *P < 0.05 and ***P < 0.001 compared to wild-type. #P < 0.05, ##P < 0.01 and ###P < 0.001 compared to mdx4cv.

https://doi.org/10.1371/journal.pgen.1009179.g003

Immunostained cryosections of TA muscles at 3 months post-injection revealed that ~60% of the total myofibers were μUtrn-positive, based on their much more intense N-terminal Utrn immunostaining (see Fig 2A, panel #2 vs. #1). The physiological data we measured thus represents the combined attributes of about 40% of the total fibers that contain little to no μUtrn (but variable levels of endogenous utrophin), and about 60% of the total fibers that contain variable μUtrn levels due to differences in fiber-to-fiber transduction.

Myofiber type differences in μUtrn expression

A fundamental question of this study is whether expression of full-length utrophin functions synergistically with the highly truncated uUtrn or whether there is a potential for steric hindrance. Considering full-length utrophin is expressed at higher levels in type 1a, 2a and 2d fibers when compared to type 2b fiber types we examined whether there is a fiber-type expression pattern of μUtrn in treated muscles. μUtrn was more favorably expressed in the fast 2b fiber types (79% μUtrn-positive) when compared with Ia (25% positive), 2a (38% positive) and 2d (43% positive) fibers at 3 months post-injection (Fig 4A–4C). Interestingly, μUtrn-positive myofibers displayed a further increase in cross-sectional area beyond that observed in mdx4cv TA muscle, regardless of fiber type (Fig 4D).

thumbnail
Download:
Fig 4. μUtrn expression mitigates dystrophic pathology and demonstrates fiber-type preferences in gastrocnemius muscles.

(A) Immunostaining for utrophin A indicating high level expression of (green), laminin A (red), and nuclei (blue). (B) Adjacent sections of μUtrn treated mdx4cv muscles with corresponding fiber typing. Symbols provide examples of 1a, 2a and 2d/x fibers expressing high levels of μUtrn. The white squares, “x’s”, triangles, and diamonds indicate type 2b, 2d/x, 2a, 1a fibers respectively. Scale bar = 50 μm. (C.) Quantification of the proportion of fiber types expressing μUtrn (Mean +/- S.D.). (D.) Myofiber area as indicated by fiber type. Box and whiskers plots displaying median +/- 75% fiber area in wild-type, mdx4cv and mdx4cv treated skeletal muscles. μUtrn expression leads to myofiber hypertrophy in all muscle fiber types. Bars show the mean +/- S.D., (N = 4). *P < 0.05 and **P < 0.01 relative to wt #P < 0.05, ##P < 0.01, ###P < 0.001 relative to untreated mdx4cv.

https://doi.org/10.1371/journal.pgen.1009179.g004

To explore whether the μUtrn fiber-type expression differences may have resulted from properties of the CMV promoter/enhancer elements, we tested a vector carrying the muscle-specific regulatory cassette CK8e (kindly provided by Dr. Stephen D. Hauschka). Initially, 2 week-old mdx4cv mice were intravenously (IV) infused with 2x1014 vg/kg of rAAV6-CK8e-Flag-μUtrn and muscles were examined 2 weeks post-injection (at 1-month of age). This experimental design focused on early stages of transgene expression, and the onset of mdx4cv mouse muscle pathology [74]. As revealed by immunostaining against the N-terminal FLAG epitope, μUtrn was found on the sarcolemma of approximately 88% of all muscle fiber types (S2A–S2C Fig; gastrocnemius muscle shown). This finding suggested that rAAV6-CK8e driven expression of μUtrn has a similar tropism for all four myofiber types. A second cohort of mice intravenously infused with rAAV6-CK8e-Flag-μUtrn was examined at a later time point (3 months of age). If uUtrn is not protecting the skeletal muscle, the muscle fibers deteriorate and regenerate leading to loss of the therapeutic cDNA and newly formed uUtrn negative myofibers. Similar to the earlier study with IM injection of rAAV6-CMV-μUtrn, we found that with IV delivery, μUtrn was expressed within a significantly greater number of type 2b myofibers compared with type 1, 2a and 2d fibers (P < 0.001; S2D–S2F Fig). Thus, the preferential expression of μUtrn in the fast 2b fibers at later time points was similar whether the CK8e (S2D–S2F Fig) or the CMV (S2G–S2I Fig) regulatory cassettes were used. Importantly, the number of myofibers expressing μUtrn at 3 months of age was significantly reduced from the earlier time points demonstrating the uUtrn was less able to protect type 1a, 2a and 2d fibers from dystrophy when compared to the type 2b fibers (S2D–S2F Fig).

As a further control, mdx4cv mice were intravenously injected with rAAV6-CK8e-μDys and analyzed 8 months later. In contrast with the μUtrn studies, expression of μDys was maintained in the vast majority of myofiber types even at 8 months, leading to a significant functional improvement of the muscles (S3 Fig). We also note that our original hinge2-μDys[75, 76] displayed stable expression for up to one year in DMD patients[77], and that a different μDys vector, rAAV6-CK8e-μDys5, showed stable expression in all striated muscles for more than 27 months in mdx4cv mice [78].

Considering uUtrn co-exists on the sarcolemma with the full-length utrophin and that full-length utrophin is found at higher levels in type Ia, 2a, and 2d fibers (Fig 5 for example, and [71]) that are less protected by uUtrn, these results raised the possibility that endogenous utrophin expression could adversely impact the therapeutic potential of μUtrn. To evaluate μUtrn expression in the absence of endogenous utrophin we examined the gastrocnemius muscles of mdx:utrn-/- (dko) mice from a previous study [47]. These mice had received an intravenous injection of 2.5x1014 vg/kg of rAAV6-CMV-μUtrn, at 3 weeks of age and were analyzed at 4 months of age. We found no preference toward μUtrn expression in the fast 2b fibers when compared with the 2a or 2d fiber types (S2J–S2L Fig). The status of type 1a fibers in this study is uncertain because there were very few type 1a myofibers in the dko gastrocnemius and only ~6% of these had detectable μUtrn (S2J–S2L Fig).

thumbnail
Download:
Fig 5. Restoration of DGC components α-dystrobrevin-2 and α1-syntrophin localization to the dystrophin-glycoprotein complex by μUtrn expression is fiber type selective.

Scale bar = 100 μm.

https://doi.org/10.1371/journal.pgen.1009179.g005

μUtrn expression in mdx4cv muscle fibers affects costamere structure

Costameres are rib-like sarcolemmal structures juxtaposed over the Z and M lines of myofibers, and are the primary sites where cytoskeletal proteins link elements of the contractile apparatus to integral and peripheral membrane protein complexes [79, 80]. Costameres can also be oriented parallel to the myofiber longitudinal axis, resulting in a rectilinear structural lattice. Historically, dystrophin represents the first costameric protein found to be associated with muscular dystrophy, displaying periodic association with costameres running transversal to the long axis of the myofiber [79, 81]. Interestingly, in mdx myofibers, the up-regulated FL-Utrn only partially compensates for the absence of dystrophin, leading to a weakened linkage between the contractile apparatus and the sarcolemma [79, 82–84]. To examine the effects of μUtrn on mdx4cv costameres, gastrocnemius muscles were removed from 3-month old FLAG-μUtrn-treated and control mdx4cv mice and cryosections were immunostained for endogenous utrophin A (using a utrophin C-terminal antibody), or for μUtrn (using a FLAG antibody). In longitudinal cryosections endogenous utrophin A was found within a standard ~2.2 μm costameric lattice, as well as between the costameric striations (S4A Fig, panel #1) in both untreated and μUtrn treated mdx4cv mice (S4A Fig, panel #3 vs_panel #6). We next examined the location of FLAG-μUtrn and found that it localized in a costameric pattern with striations that were only ~0.8 μm apart (S4B and S4C Fig (P < 0.001)). However, μUtrn localizes in normal, 2.2 μm striations in the absence of full-length Utrn, as seen in treated mdx:utrn-/- muscles (S4D Fig). Thus, high-level expression of FLAG-μUtrn in mdx4cv mice leads to the localization of μUtrn in closely spaced striations that co-exist with the normal, FL-Utrn containing costameres.

Assembly of the dystrophin-glycoprotein complex following μUtrn treatment

Expression of μDys has been shown to restore assembly and sarcolemmal localization of the dystrophin-glycoprotein complex (DGC) [9, 32, 85–87], so we asked whether μUtrn expression also restores DGC components in mdx4cv muscles. This was tested utilizing the same mice described for the rAAV6-CMV-μUtrn IM injection study from Fig 2. Serial cryosections from injected gastrocnemius muscles were immunostained to detect myosin heavy chain isoforms associated with different muscle fiber types (Fig 5A–5C), utrophin (Fig 5D–5F), and the representative DGC components β-dystroglycan (β-Dgn) (Fig 5G–5I), δ-sarcoglycan (δ-Sarc) (Fig 5J–5L), α-dystrobrevin-2 (α-Db2) (Fig 5M–5O), α-1-syntrophin (α1-Syn) (Fig 5P–5R) and neuronal nitric oxide synthase (nNOS) (Fig 5S–5U).

As expected, endogenous FL-Utrn was only expressed at low levels in wild-type muscles (Fig 5D), but was up-regulated in mdx4cv muscle fibers (Fig 5E)[88–91]. However, the relative sarcolemmal intensity of endogenous utrophin A immunostaining was highly variable between and within different fiber types (e.g., Fig 5B and 5E). In contrast, numerous myofibers within rAAV6-CMV-μUtrn IM injected mdx4cv muscles exhibited intense utrophin immunostaining, with type 2b fibers displaying the highest relative intensities (e.g., Fig 5F). The DGC components, β-Dgn, δ-Sarc were broadly restored in myofiber types (Fig 5, 5I vs. 5H, and 5L vs. 5K), while α-Dbn-2, and α1-Syn were most strongly re-localized in 2b fibers (Fig 5, 5O vs. 5N, and 5R vs. 5Q), which displayed the highest expression of μUtrn. In contrast, nNOS remained relatively absent from the sarcolemma (Fig 4U vs 4S), even though α1-Syn, a DGC component with which nNOS and endogenous utrophin are known to interact [92, 93], was re-localized to the sarcolemma. This observation has been confirmed in previous work where it was shown that the α-Syn binding motif within dystrophin spectrin-like repeat-17 enables recruitment of nNOS to the sarcolemma[32, 33, 52]. These results show that μUtrn, like utrophin A, does not localize nNOS to the sarcolemma [87]. The ability of μUtrn to localize α1-Syn is presumably due to additional components of the DGC, such as α-Db isoforms that are known to interact with α1-Syn, and potentially the sarcoglycans [94]. These results thus indicate that delivery of AAV6-CMV-μUtrn to mdx4cv mouse muscles localizes most, but not all, dystrophin glycoprotein-complex proteins to the sarcolemma.

Influence of μUtrn on the structure of neuromuscular junctions

The acetylcholine receptor (AChR) clusters on the postsynaptic membranes of neuromuscular junctions (NMJs) in wild-type mice mature into pretzel-like profiles that exhibit generally continuous junctions (defined here as a NMJ that has three or less continuous segments) when viewed en face (Fig 6A, panel 1). These profiles are known to further fragment upon skeletal muscle necrosis in mdx4cv and mdx:utrn-/- mice [18–20, 74]. We found that μUtrn expression in gastrocnemius muscles of mdx4cv and mdx:utrn-/- mice prevented the formation of fragmented synapses (Fig 6A, panel #3 vs #2, and panel #5 vs #4). Importantly, the overall continuity of junctional membranes was significantly improved in μUtrn-treated muscles (Fig 6B). We also examined electron micrographs of NMJs in these mice and found, as in normal muscle fibers, that the presynaptic motor nerve terminal directly abuts the postsynaptic apparatus and that the presynaptic terminal contains folds [black arrow head, (wt) vs black arrow, (mdx+μUtrn)] that invaginate into the muscle (Fig 6A, compare panel #’s 6–10).

thumbnail
Download:
Fig 6. μUtrn expression partially restores the structure of neuromuscular junctions.

(A) Top panel: AChR cluster visualization in the postsynaptic apparatus reveals that μUtrn expression prevents the fragmentation of synapses seen in mdx4cv and dko muscles. Scale bar = 10 μm. Lower panel: Electron microscopic images of neuromuscular synapses reveals that the synaptic folds in wild-type mice (arrow head) are shallower and less in number in muscles from mdx4cv mice and dko mice. μUtrn restores the depth, but not the number of synaptic folds. However, the synaptic folds are highly branched in the mdx4cv mice treated with rAAV-μUtrn. Scale bar = 0.5 μm. (B) Mean +/- S.D. of continuous synapses. (C) Mean +/- S.D. of fold lengths in the postsynaptic apparatus. (D) Mean +/- S.D. of the number of postsynaptic folds/μm. *P < 0.05, **P < 0.001, and ***P < 0.001 compared to wild-type. ##P < 0.01 and ###P < 0.001 compared to mdx4cv. @P < 0.05 and @@@P < 0.001 compared to dko.

https://doi.org/10.1371/journal.pgen.1009179.g006

In wild type muscles utrophin is primarily restricted to the crests of folds whereas dystrophin is found in the troughs of folds [95, 96]. Utrophin is also restricted to the crests of folds in NMJs of mdx skeletal muscles (S5 Fig, panel #5). We found that the NMJs in mdx4cv postsynaptic membranes have a small, but significant reduction in the length and number of folds (Fig 6C & 6D), and that μUtrn is mis-localized to the troughs of the synaptic folds in treated mdx4cv muscles (S5 Fig, panel #6). μUtrn delivery restored the length of synaptic folds in mdx4cv muscles to depths similar to those in wild-type muscles (Fig 6A, panels #6–8, and 6C). Interestingly however, while μUtrn did not restore the number of post-synaptic folds in mdx4cv mice (Fig 6D), the folds in μUtrn-treated mice became highly branched (Fig 6A, panel #8). Expression of μUtrn did restore the number of folds in the NMJs of mdx:utrn-/- muscles to the levels found in mdx4cv muscles (Fig 6A panels #5 & 10, 6D).

Influence of μUtrn on the structure of myotendinous junctions

Treatment of mdx4cv mice with a first-generation μDys(ΔR4-R23/ΔCT) leads to myotendinous strain injury and “ringbinden” or ringed fiber formation in gastrocnemius muscles [19, 26, 39]. This is associated with the presence of a polyproline motif within the ‘Hinge-2’ domain of this particular μDys [19, 26, 39]. We therefore asked whether expression of the analogous μUtrn would lead to similar deleterious effects (Fig 7). Electron micrographic analysis of transverse gastrocnemius muscle sections from untreated wt, mdx4cv, mdx:utrn-/-, as well as in mdx4cv or mdx:utrn-/- mice treated with μUtrn revealed no ringed fibers in any of the muscles (Fig 7A, panels #3 and #5). Thus, the polyproline motif from utrophin hinge 2 does not adversely affect muscle ultrastructure.

thumbnail
Download:
Fig 7. μUtrn expression partially restores the structure of myotendinous junctions without leading to ringed fiber formation.

(A) Top panel: Electron microscopy of transverse sections of gastrocnemius muscles. Scale bar = 2 μm. Lower panel: Longitudinal sections of Achilles myotendinous junctions. Note the loss of folds in mdx4cv and dko mice is partially restored by μUtrn expression. Scale bar = 5 μm. (B) Mean +/- S.D. length of folds. (C) Mean +/- S.D. fold per μm of MTJ. (D) Mean +/- S.D. increase in membrane length brought about by the MTJ folds.

https://doi.org/10.1371/journal.pgen.1009179.g007

To assess the presence of endogenous utrophin and μUtrn within MTJs we immunostained cryosections with a C-terminal antibody (to detect endogenous utrophin) and with the FLAG antibody (to detect FLAG-μUtrn). Both types of utrophin colocalized within folds in the Achilles myotendinous junctions [S6 Fig, where each panel shows the myofiber(s) integrated into the tendon at the base of the image(s)]. Since the folds in MTJs play critical roles in reducing membrane shear stress during muscle contraction [22], we also analyzed electron micrograph sections to determine the lengths of the MTJ folds. The MTJ folds were shorter in muscles from mdx4cv mice than in wild type controls, as indicated by the white arrows (Fig 7A; compare panel #6 vs #7, and Fig 7B). However, the folds were also more numerous than in controls (Fig 7C), resulting in a reduction in the total length of membrane provided by the junctional folds when compared to wild-type muscles (Fig 7D). μUtrn treatment partially restored the MTJ fold length and number in mdx4cv muscles (Fig 7B and 7C); thereby essentially restoring the total length of membrane provided by the folds (Fig 7D).

Discussion

Here we demonstrate that μUtrn improves the dystrophic pathophysiology of mdx4cv muscles, as well as the maturation and maintenance of the neuromuscular and myotendinous junctions. Histologically, following μUtrn treatment there was an abrupt reduction in the number of myofibers undergoing regeneration as indicated by central nucleation. We also observed the restoration of DGC components β–Dgn and δ-Sgn, however the localization of α-Db2 and α1-Syn was skewed toward fast 2b fiber expression. Indeed, at longer time-points within our study the improvement in pathophysiology appears to primarily stem from the stable expression of μUtrn within fast 2b fibers rather than the 1a, 2a and 2d/x fiber types irrespective of the transcriptional regulatory cassette used to drive expression. These observations have potentially important implications for the treatment of DMD skeletal muscles with AAV-delivered μUtrn.

Does steric hindrance between μUtrn and endogenous utrophin impact efficacy?

A fundamental question of this study is not only could uUtrn compensate for the lack of dystrophin, but whether uUtrn could function optimally when co-existing with the endogenous full-length utrophin. More specifically, is there potential for steric hindrance between the full-length utrophin and the smaller μUtrn that could impact the function and survival of muscle cells? Slower fiber types have long been known to have slightly higher levels of endogenous utrophin expression and this correlates with a slightly milder dystrophic phenotype in untreated mdx mice[67–69]. Consistent with this, in mdx mice, we previously found there is more endogenous utrophin in Type 1a, 2a and 2d fiber types, when compared to fast Type 2b[71]. Strikingly, we found that uUtrn is better able to prevent the dystrophic pathology in Type 2a and 2d fibers in mdx/utrn-/- mice lacking both dystrophin and utrophin when compared to the same muscle fiber types in mdx mice (Compare S2J–S2L to S2D–S2I Fig). This phenotype was likely unique to μUtrn treatment as delivery of second-generation uDys[39] with the same vector and promoter was able to prevent the dystrophic pathology of mdx4cv mice, independent of fiber-type. Furthermore, uUtrn profoundly reduced the spacing of costameres in mdx4cv mice (S4 Fig) providing a unique environment for steric hindrance with full-length utrophin within the sarcolemma.

Importantly, steric hindrance requires that both the full-length utrophin and uUtrn are on the sarcolemma at the same time. Our time-course study demonstrates we targeted the majority of muscle fibers (88%) with the therapeutic at the early age when endogenous utrophin is present on the sarcolemma. We originally anticipated that the expression of μUtrn would prevent the dystrophic pathology and allow the endogenous utrophin to follow its natural time course, and dissipate from the sarcolemma as it would with dystrophin. However, Fig 2A, panels 2 & 4 shows this wasn’t the case, as low levels of the endogenous utrophin can be found on the same fibers as the μUtrn at 3 months of age. The greater levels of full-length utrophin in type 1a, 2a and 2d sarcolemma could sterically hinder the μUtrn more than in fast 2b fibers where full-length utrophin is minimal[71]. Steric hindrance between full-length utrophin and μUtrn leave the skeletal muscles more susceptible to contraction-induced injury, leading to the death of the muscle fibers and regeneration of the myotubes without the uUtrn therapeutic. This would explain why we see broad μUtrn expression and prevention of dystrophy in fast 2b fibers, but less so in other fiber types. Together, our results support an in vivo condition where the stoichiometry of full-length utrophin and μUtrn at the sarcolemma of skeletal muscle fibers could impact the efficacy of the therapeutic.

We also note that in a recent study with mdx mice and cxmd canines treated with AAV-mediated micro-utrophin demonstrated impressive efficacy at early timepoints (~2 weeks post-delivery)[46], which was also seen in dko mice[47], and to a large degree here as well. However, in the recent[46] and the present studies the functional benefit seen in mdx4cv mice waned over time in fiber types 2A, 1A, & 2D, possibly due to competition with fl utrn. The sustained uUtrn expression in fast 2B fibers in the present study suggests the mdx mice did not outgrow expression as previously postulated[46], a conclusion further supported by the sustained uDystrophin expression observed for at least 8 months and up to 2 years in all fiber types in mdx mice, and for >1 year in DMD patients [77, 78]. The relative expression levels of fl utrn in various fiber-types and between species such as mice, dogs and humans is not well established and detailed biodistribution and time course studies will be required to understand the longevity of the therapy. Further, the canine studies were followed only for a relatively short time period, such that fiber-type expression levels might potentially wane over time.

Neuromuscular synapse

The neuromuscular junction contains distinct structural features that ensure nerve evoked stimulation of the muscle exceeds that needed to generate an action potential in the postsynaptic membrane [97]. The presynaptic nerve terminal contains active zones where quanta of acetylcholine are released onto AChR clusters on the crests of the postsynaptic folds [95, 96]. The postsynaptic folds contain a high concentration of voltage gated sodium channels that reduce the threshold required to generate endplate currents [98]. The number of quanta reduces with repeat stimulation of the nerve during normal muscle activity [99], but the sodium channels in the folds ensure the safety of transmission is maintained [98–100]. The depth and number of folds determines the concentration of voltage gated sodium channels [19, 101]. Thus, the reduction in depth and number of folds could contribute to the functional deficits in synaptic transmission in mdx4cv mice [98, 102]. Here we found that μUtrn was able to restore the depth, but not the number of fold openings in mdx4cv mice. However, μUtrn expression did lead to a profound increase in fold branching. Utrophin is normally localized to the crests of folds, and dystrophin is primarily localized with the troughs of folds along with voltage gated sodium channels. Therefore, it is possible that the mislocalization of μUtrn increased the branching. In support of this hypothesis, utrophin is required to maintain the fold openings at the neuromuscular junction [103]. We previously found that miniaturized dystrophins can restore the depth and number of folds [19, 39]. Therefore, dystrophin and utrophin are both required for normal development of the synaptic folds. The neuromuscular junctions in humans are smaller than mice and the folds are deeper, suggesting the safety-factor of synaptic transmission relies more on the voltage gated sodium channels [97]. Therefore, a loss of synaptic folds and inclusive sodium channels resulting in decreased synaptic currents within the neuromuscular junctions of DMD patients could potentially reduce the neuromuscular transmission contributing to fatigue. An increase in fold branching could potentially compensate for the lack of fold openings in DMD to restore the safety of neuromuscular synaptic transmission.

Myotendinous junction

The myotendinous junction is a major site of force transfer in skeletal muscles [22]. The folds within the MTJ reduce membrane stress under shear [22]. The depth of the folds is reduced within the Achilles MTJ in mdx4cv mice and in some DMD patients [21, 23, 24, 26]. Further, the MTJ is a primary site of contraction-induced injury in mdx4cv mice and some DMD patients [21, 23, 24, 26]. Treatment with μUtrn partially increased the MTJ folds in mdx4cv mice and restored the sarcomere attachments in the dko mice. Importantly, μUtrn did not lead to chronic myotendinous strain injury or ringed fibers despite containing a polyproline site in hinge 2 [39]. Therefore, the structure and function of μUtrn likely differs from that of an analogous μDys(ΔR4-R23/ΔCT) that did lead to myotendinous strain injury and ringed fiber formation when expressed in mdx4cv muscles.

In conclusion, μUtrn was able to replace most functions of dystrophin at the sarcolemma, neuromuscular junctions, and myotendinous junctions of dystrophin-deficient mdx4cv mice. However, we also present several lines of in vivo evidence consistent with steric hindrance between the full-length endogenous utrophin and uUtrn, which could impact the dystrophic pathophysiology in a myofiber type selective manner. Further studies are needed to better understand the stoichiometry of steric hindrance to predict its relevance in large animal models and humans.

Materials and methods

Mice and ethics statement

C57Bl/6 mice and mdx4cv mice were utilized in this study. The mdx4cv mice were genotyped by sequencing as previously described [104]. All Animal experiments were performed in accordance with and approval by the Institutional Animal Care and Use Committee of the University of Washington under protocol 3333–01. The UW guidelines are at least as protective as those of the National Institutes of Health, they conform to all applicable laws and regulations, they meet prevailing community standards for responsible scientific research and were applied throughout the project to ensure the humane treatment of all animals involved in the project.

Viral vector production and injection

The μUtrn cDNA sequence was codon-optimized using GenScript (Piscataway, NJ). The rAAV6-CK8-codon optimized μUtrn and rAAV6-CMV-μUtrn (not codon optimized) expression vectors were sequenced and co-transfected with the pDGM6 packaging plasmid into HEK293 cells to generate recombinant AAV vectors comprising serotype 6 capsids. Vectors were harvested, purified, and quantitated as described previously [73]. The rAAV6-μUtrns were formulated in Hanks’ balanced salt solution and injected either directly into the gastrocnemius muscles or intravenously by retro-orbital injection at two weeks of age while the mice were anaesthetized with isofluorane.

Histology

Muscles were frozen directly in OCT cooled in 2-methylbutane in liquid N2. Ten micrometer transverse sections of skeletal muscles were immunostained as previously described [71]. Briefly adjacent sections were immunostained with conjugated monoclonal antibodies to myosin heavy chain to identify fiber-types as previously described [105], N terminal utrophin antibody, C-terminal utrophin antibody (both 1:800; and kindly provided by Stanley Froehner, University of Washington, Seattle, USA), α2-laminin (1:800; SIGMA, St. Louis MO), and hematoxylin and eosin using manufacturer protocols (Electron Microscopy Sciences; Hatfeild, PA). For detecting DGC components, adjacent frozen sections were immunostained with α-dystrobrevin 2 (1:1000), α1-syntrophin (1:500; the latter two antibodies were kind gifts from Stanley Froehner), β-dystroglycan (1:100; BD Biosciences, San Jose, CA), δ-sarcoglycan (1:40; Leica Biosystems, Buffalo Grove, IL), or nNOS (1,100; Invitrogen, Carlsbad, CA). For detecting AChRs, cryosections we incubated in α-bungarotoxin conjugated to TRITC (1,800; Invitrogen, Carlsbad, CA). All fluorescent immunostained sections were coverslipped with ProLong Gold mounting medium containing DAPI (Invitrogen, Carlsbad, CA). Sections were imaged with either a Leica SP5 confocal or an Olympus SZX16 dissection fluorescent microscope.

Immunoblotting

Western blots were performed on whole muscle lysates as previously described [26]. Briefly, the gastrocnemius muscles treated mdx4cv muscles and contralateral controls (n = 4) were ground in liquid N2 and homogenized in extract buffer (50 mM Tris-HCl, 150 mM NaCl, 0.2% SDS, 24 mM Na deoxycholate, 1% NP40, 47.6 mM Na Fluoride, 200 mM Na Orthovanadate, Roche, Basel, CH). Protein concentration of whole muscle was determined by Coomassie Plus Bradford Assay (Thermoscientific, Rockford, IL). Equal amounts of protein (20 μg) were resolved on a 4–12% SDS polyacrylamide gel. The blots were incubated in N-terminal anti-utrophin (1:1000; kind gift from Stanley C. Froehner) overnight at 4°C. The GAPDH antibody (1:50,000; Sigma, St. Louis, MO) was used as a loading control as its expression was unchanged when comparing the treated and untreated mdx4cv muscles. The primary antibodies were detected with IgG HRP secondary antibodies (1:25,000; Jackson ImmunoResearch Labs). The blots were developed with ECL plus (Thermoscientific, Rockford, IL) and scanned with the Storm 860 imaging system (GE Healthcare Lifesciences, Piscataway, NJ). The band intensity was measured using Image J software (NIH).

Real time PCR

To isolate the RNA, approximately 20μg of gastrocnemius muscle previously ground by mortar and pestle in liquid N2 was used to extract total RNA following manufacturer’s instructions (TRI Reagent, Molecular Research Center, Inc. Cincinnati, OH). The pelleted RNA was suspended in 50 μl nuclease free elution solution (Ambion Inc., Austin, TX). Five μg of total RNA was treated with Turbo DNA-free (Ambion Inc., Austin, TX) in order to remove trace amounts of contaminating DNA. The DNAase Treated RNA (0.5μg) was diluted to 8μl with nuclease free water followed by use of the SuperScript III First-Strand Synthesis kit (Invitrogen, Carlsbad, CA) to generate cDNA. Subsequently 2μl of the cDNA was used for qPCR with utrophin primer-probe sets. The mouse utrophin oligonucleotide sequences were: Forward 5’- ACCAGCTGGACCGATGGA-3’, Reverse 5’- CTCGTCCCAGTCGAAGAGATCT-3’, Probe 5’-6FAM- CGTTCAACGCCGTGCTCCACC-3’-BHQa1-Q. The primer sequences for the μUtrn H2-R22 unique junction were Forward 5’-GCGATAACCTGGAGACCTGAAG-3’, reverse 5’-TTTATTACTAGCCACCGGTATCGAT-3’, probe 6FAM-ATTCATCCGGCCAACCAATGTTCTCG. As a reference gene the oligonucleotide set was used to target the mouse Ywhaz gene sequence (Tyrosine 3-monooxygenase; [106]): Forward 5’- GCTGGTGATGACAAGAAAGGAAT-3’, Reverse 5’- GGTGTGTCGGCTGCATCTC-3’, Probe 5’-6FAM-TGGACCAGTCACAGCAAGCATACCAAGA-3’-BHQa1-Q.

Muscle fiber areas

The muscle fiber areas were quantitated for each fiber-type using the FIJI Open Source image processing software package based on ImageJ, as previously described [71].

Skeletal muscle physiology

The tibialis anterior muscle physiology was performed as previously described [37, 39, 47, 73, 107].

Electron microscopy

The electron microscopy was performed on transverse and longitudinal sections of the gastrocnemius muscles as previously described [26]. The junctional fold number and lengths were measured from N = 4 mice at 3 months of age in mdx mice treated with the rAAV6-CK8-μUtrn and the contralateral control using FIJI computer program. The counts represent the fold numbers and lengths from all fibers.

Quantitation of neuromuscular synapses

Neuromuscular synapses were analyzed in wholemount immunostained teased muscle fibers and quantitated as previously described [19, 39]. Synapses were quantitated from N = 4 mdx4cv or dko muscles treated with rAAV6-CK8-mUtrn or rAAV6-CMV-μUtrn respectively.

Statistics

The data were compared using a one-way ANOVA with a Tukey post-test that compares all data sets with a Student’s t-test. All data analyses were performed using the PRISM software.

Supporting information

S1 Fig.

(A.) μUtrn expression reduces the number of fibers undergoing regeneration. The number of developmental myosin heavy chain positive fibers in the gastrocnemius muscles are displayed at 4 months of age. Data are shown as mean +/- S.D. **P < 0.01 compared to wild-type. ##P < 0.01.

https://doi.org/10.1371/journal.pgen.1009179.s001

(TIF)

S2 Fig. Fiber-type expression of μUtrn expression is influenced by expression of endogenous full-length utrophin.

A) μUtrn is present in all fiber-types 2 weeks after vector administration at similar levels each approaching ~90%; B) corresponding myofiber typing for the 2 week time point; and C) Quantification of the proportion of fiber types expressing μUtrn (Mean +/- S.D.). D) μUtrn is unable to prevent necrosis in most 1a, 2a and 2d/x fiber types at 3 months of age. E) Representative fiber typing; F) Mean +/- S.D. proportion of μUtrn-positive fiber types. ***P < 0.001 compared to the fast 2b fibers at 3 months of age. G) μUtrn is predominantly expressed in the fast 2b fibers when driven by the CMV promoter. H) Representative fiber typing; I) Mean +/- S.D. proportion of μUtrn positive fiber types. ***P < 0.001 compared to the fast 2b fibers at 4 months of age. J) μUtrn was not selective for the fast 2b fibers in mdx4cv:utrophin double knockout (dko) mice. K) Representative fiber typing; & L) Mean +/- S.D. proportion of μUtrn positive fiber types. *P < 0.05 compared to the 2a, 2b and 2d fiber types at 4 months of age. Scale bar = 100 μm.

https://doi.org/10.1371/journal.pgen.1009179.s002

(TIF)

S3 Fig. Intravenous administration of rAAV6-CK8-microdystrophin(ΔH2-21/ΔCT+H3) vectors to mdx4cv mice results widespread expression & increased muscle function at 9 months post-administration.

In comparison to untreated mdx4cv, the gastrocnemius muscles of μDys treated mdx4cv mice exhibited (A) increased force generating capacity; (B) increased specific force (sPo); (C) decreased susceptibility to eccentric contraction-induced injury; (D) increased recovery force generation; and (E) Display of broad immunostaining for dystrophin and (F.) corresponding adjacent H&E. Data are shown as mean +/- S.D. **P < 0.01 compared to wild-type. ##P < 0.01, ###P < 0.001, compared to mdx4cv. sPo, specific force; WT, wild type; hematoxylin & eosin, H&E. Scale bar = 50 μm.

https://doi.org/10.1371/journal.pgen.1009179.s003

(TIF)

S4 Fig. Influence of μUtrn localization on the costameres.

(A) Utrophin localizes in a rectilinear pattern with α-sarcomeric actin in mdx4cv and rAAV-μUtrn treated muscles (S4 Fig, panels 3 & 6). Note however, the prominent utrophin localization between the large costameric striations. Scale bar = 10 μm. (B) Localization of μUtrn with the FLAG antibody revealed the costameric striations to be very close together. Scale bar = 10 μm. C) Immunostaining of μUtrn with the utrophin A antibody reveals the costameric striations in dko mice treated with AAV6-CMV-μUtrn. Scale bar = 10 μm. Mean +/- S.D. distance between the costameric striations in mdx4cv controls and the FLAG-μUtrn expressing muscles. ###P < 0.001.

https://doi.org/10.1371/journal.pgen.1009179.s004

(TIF)

S5 Fig. μUtrn localization within neuromuscular synapses of mdx mouse muscles.

Note that utrophin (green) localizes on the crests of the folds in mdx mice (arrow in top panel inset). However, FLAG-μUtrn was found within the folds (arrow in lower panel inset). Note also the lack of subsynaptic nuclei (blue, DAPI) in the mdx myofiber, but not the μUtrn/mdx myofiber. This mdx myofiber (top panel) has regenerated as revealed by the centrally-located nucleus. α-bungaratoxin (αBTX) staining is shown in red. Scale bar = 10 μm.

https://doi.org/10.1371/journal.pgen.1009179.s005

(TIF)

S6 Fig. μUtrn within the mdx myotendinous junctions.

Note that utrophin and FLAG-μUtrn (green) were found in the folds (merged panel, arrows). α2-laminin is shown in red, while DAPI is shown in blue. Scale bar = 20 μm.

https://doi.org/10.1371/journal.pgen.1009179.s006

(TIF)

Acknowledgments

We would like to thank Eric Finn and James Allen for assistance with vector production, and Bobbie Schneider at the Fred Hutchinson Cancer Research Centre for assistance with electron microscopy.

References

  1. 1. Hoffman EP, Brown RH Jr., Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–28. Epub 1987/12/24. pmid:3319190.
  2. 2. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell. 1987;50(3):509–17. Epub 1987/07/31. pmid:3607877.
  3. 3. Bhasin N, Law R, Liao G, Safer D, Ellmer J, Discher BM, et al. Molecular extensibility of mini-dystrophins and a dystrophin rod construct. Journal of molecular biology. 2005;352(4):795–806. Epub 2005/09/06. pmid:16139300.
  4. 4. Mirza A, Sagathevan M, Sahni N, Choi L, Menhart N. A biophysical map of the dystrophin rod. Biochimica et biophysica acta. 2010;1804(9):1796–809. Epub 2010/04/13. pmid:20382276.
  5. 5. Henderson DM, Lee A, Ervasti JM. Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation. Proceedings of the National Academy of Sciences of the United States of America. 2010;107(21):9632–7. Epub 2010/05/12. pmid:20457930; PubMed Central PMCID: PMC2906886.
  6. 6. Ervasti JM, Sonnemann KJ. Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol. 2008;265:191–225. pmid:18275889.
  7. 7. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-glycoprotein complex. Cell. 1991;66(6):1121–31. pmid:1913804.
  8. 8. Koenig M, Kunkel LM. Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. The Journal of biological chemistry. 1990;265(8):4560–6. Epub 1990/03/15. pmid:2407739.
  9. 9. Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990;345(6273):315–9. pmid:2188135.
  10. 10. Ervasti JM. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta. 2007;1772(2):108–17. pmid:16829057.
  11. 11. Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature. 2008;456(7221):511–5. Epub 2008/10/28. nature07414 [pii] pmid:18953332; PubMed Central PMCID: PMC2588643.
  12. 12. Grady RM, Grange RW, Lau KS, Maimone MM, Nichol MC, Stull JT, et al. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol. 1999;1(4):215–20. pmid:10559919
  13. 13. Brooks SV. Rapid recovery following contraction-induced injury to in situ skeletal muscles in mdx mice. Journal of muscle research and cell motility. 1998;19(2):179–87. Epub 1998/04/16. pmid:9536444.
  14. 14. Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. Journal of muscle research and cell motility. 2001;22(5):467–75. Epub 2002/04/20. pmid:11964072.
  15. 15. Faulkner JA, Ng R, Davis CS, Li S, Chamberlain JS. Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clinical and experimental pharmacology & physiology. 2008;35(7):725–9. Epub 2008/01/25. pmid:18215182.
  16. 16. Moens P, Baatsen PH, Marechal G. Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil. 1993;14(4):446–51. pmid:7693747.
  17. 17. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proceedings of the National Academy of Sciences of the United States of America. 1993;90(8):3710–4. Epub 1993/04/15. pmid:8475120; PubMed Central PMCID: PMC46371.
  18. 18. Lyons PR, Slater CR. Structure and function of the neuromuscular junction in young adult mdx mice. Journal of neurocytology. 1991;20(12):969–81. Epub 1991/12/01. pmid:1686056.
  19. 19. Banks GB, Chamberlain JS, Froehner SC. Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci. 2009;40(4):433–41. Epub 2009/01/28. S1044-7431(08)00317-5 [pii] pmid:19171194; PubMed Central PMCID: PMC2826111.
  20. 20. Faber RM, Hall JK, Chamberlain JS, Banks GB. Myofiber branching rather than myofiber hyperplasia contributes to muscle hypertrophy in mdx mice. Skeletal Muscle. 2014;4(10). pmid:24910770
  21. 21. Nagao H, Morimoto T, Sano N, Takahashi M, Nagai H, Tawa R, et al. [Magnetic resonance imaging of skeletal muscle in patients with Duchenne muscular dystrophy—serial axial and sagittal section studies]. No to hattatsu Brain and development. 1991;23(1):39–43. Epub 1991/01/01. pmid:1994993.
  22. 22. Tidball JG. Force transmission across muscle cell membranes. Journal of biomechanics. 1991;24 Suppl 1:43–52. Epub 1991/01/01. pmid:1791181.
  23. 23. Hasegawa T, Matsumura K, Hashimoto T, Ikehira H, Fukuda H, Tateno Y. [Intramuscular degeneration process in Duchenne muscular dystrophy—investigation by longitudinal MR imaging of the skeletal muscles]. Rinsho shinkeigaku = Clinical neurology. 1992;32(3):333–5. Epub 1992/03/01. pmid:1628461.
  24. 24. Law DJ, Caputo A, Tidball JG. Site and mechanics of failure in normal and dystrophin-deficient skeletal muscle. Muscle & nerve. 1995;18(2):216–23. Epub 1995/02/01. pmid:7823981.
  25. 25. Law DJ, Tidball JG. Dystrophin deficiency is associated with myotendinous junction defects in prenecrotic and fully regenerated skeletal muscle. The American journal of pathology. 1993;142(5):1513–23. Epub 1993/05/01. pmid:8494050; PubMed Central PMCID: PMC1886922.
  26. 26. Banks GB, Combs AC, Chamberlain JR, Chamberlain JS. Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Human molecular genetics. 2008;17(24):3975–86. Epub 2008/09/19. ddn301 [pii] pmid:18799475; PubMed Central PMCID: PMC2638580.
  27. 27. Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP. Identification and characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem. 1995;270(45):27305–10. pmid:7592992.
  28. 28. Winder SJ, Gibson TJ, Kendrick-Jones J. Dystrophin and utrophin: the missing links! FEBS letters. 1995;369(1):27–33. Epub 1995/08/01. pmid:7641878.
  29. 29. Banks GB, Chamberlain JS. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol. 2008;84:431–53. Epub 2009/02/03. S0070-2153(08)00609-1 [pii] pmid:19186250.
  30. 30. Legardinier S, Raguenes-Nicol C, Tascon C, Rocher C, Hardy S, Hubert JF, et al. Mapping of the lipid-binding and stability properties of the central rod domain of human dystrophin. Journal of molecular biology. 2009;389(3):546–58. Epub 2009/04/22. pmid:19379759.
  31. 31. Amann KJ, Renley BA, Ervasti JM. A cluster of basic repeats in the dystrophin rod domain binds F-actin through an electrostatic interaction. The Journal of biological chemistry. 1998;273(43):28419–23. Epub 1998/10/17. pmid:9774469.
  32. 32. Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, et al. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. J Clin Invest. 2009;119(3):624–35. Epub 2009/02/21. 36612 [pii] pmid:19229108; PubMed Central PMCID: PMC2648692.
  33. 33. Adams ME, Odom GL, Kim MJ, Chamberlain JS, Froehner SC. Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16–17. Hum Mol Genet. 2018;27(17):2978–85. Epub 2018/05/24. pmid:29790927; PubMed Central PMCID: PMC6097012.
  34. 34. Belanto JJ, Mader TL, Eckhoff MD, Strandjord DM, Banks GB, Gardner MK, et al. Microtubule binding distinguishes dystrophin from utrophin. Proc Natl Acad Sci U S A. 2014;111(15):5723–8. Epub 2014/04/08. [pii]. pmid:24706788; PubMed Central PMCID: PMC3992671.
  35. 35. Odom GL, Banks GB, Schultz BR, Gregorevic P, Chamberlain JS. Preclinical studies for gene therapy of Duchenne muscular dystrophy. J Child Neurol. 2010;25(9):1149–57. pmid:20498332.
  36. 36. Goyenvalle A, Seto JT, Davies KE, Chamberlain J. Therapeutic approaches to muscular dystrophy. Human molecular genetics. 2011;20(R1):R69–78. Epub 2011/03/26. pmid:21436158; PubMed Central PMCID: PMC3095062.
  37. 37. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med. 2006;12(7):787–9. pmid:16819550.
  38. 38. Wang B, Li J, Fu FH, Xiao X. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2009;27(4):421–6. Epub 2008/11/01. pmid:18973234.
  39. 39. Banks GB, Judge LM, Allen JM, Chamberlain JS. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet. 2010;6(5):e1000958. Epub 2010/05/27. pmid:20502633; PubMed Central PMCID: PMC2873924.
  40. 40. Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther. 2012;20(8):1501–7. pmid:22692496; PubMed Central PMCID: PMC3412492.
  41. 41. Shin JH, Pan X, Hakim CH, Yang HT, Yue Y, Zhang K, et al. Microdystrophin ameliorates muscular dystrophy in the canine model of duchenne muscular dystrophy. Mol Ther. 2013;21(4):750–7. Epub 2013/01/16. [pii]. pmid:23319056; PubMed Central PMCID: PMC3616540.
  42. 42. Crudele JM, Chamberlain JS. AAV-based gene therapies for the muscular dystrophies. Hum Mol Genet. 2019;28(R1):R102–R7. Epub 2019/06/27. pmid:31238336; PubMed Central PMCID: PMC6796995.
  43. 43. Flanigan KM, Campbell K, Viollet L, Wang W, Gomez AM, Walker CM, et al. Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther. 2013;24(9):797–806. Epub 2013/09/10. pmid:24010700; PubMed Central PMCID: PMC3768239.
  44. 44. Fairclough RJ, Wood MJ, Davies KE. Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nature reviews Genetics. 2013;14(6):373–8. Epub 2013/04/24. pmid:23609411.
  45. 45. Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest. 2013;123(12):5310–8. Epub 2013/11/16. pmid:24231351; PubMed Central PMCID: PMC3859421.
  46. 46. Song Y, Morales L, Malik AS, Mead AF, Greer CD, Mitchell MA, et al. Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models. Nat Med. 2019;25(10):1505–11. pmid:31591596.
  47. 47. Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther. 2008;16(9):1539–45. pmid:18665159; PubMed Central PMCID: PMC2643133.
  48. 48. Rybakova IN, Ervasti JM. Identification of spectrin-like repeats required for high affinity utrophin-actin interaction. The Journal of biological chemistry. 2005;280(24):23018–23. Epub 2005/04/14. pmid:15826935.
  49. 49. Prochniewicz E, Henderson D, Ervasti JM, Thomas DD. Dystrophin and utrophin have distinct effects on the structural dynamics of actin. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(19):7822–7. pmid:19416869; PubMed Central PMCID: PMC2683112.
  50. 50. Rybakova IN, Humston JL, Sonnemann KJ, Ervasti JM. Dystrophin and utrophin bind actin through distinct modes of contact. The Journal of biological chemistry. 2006;281(15):9996–10001. pmid:16478721.
  51. 51. Lin AY, Prochniewicz E, Henderson DM, Li B, Ervasti JM, Thomas DD. Impacts of dystrophin and utrophin domains on actin structural dynamics: implications for therapeutic design. J Mol Biol. 2012;420(1–2):87–98. Epub 2012/04/17. [pii]. pmid:22504225; PubMed Central PMCID: PMC3367031.
  52. 52. Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R, et al. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. Journal of cell science. 2010;123(Pt 12):2008–13. Epub 2010/05/21. pmid:20483958; PubMed Central PMCID: PMC2880012.
  53. 53. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, et al. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med. 1998;4(12):1441–4. pmid:9846586.
  54. 54. Ervasti JM, Kahl SD, Campbell KP. Purification of dystrophin from skeletal muscle. The Journal of biological chemistry. 1991;266(14):9161–5. pmid:2026615.
  55. 55. Ohlendieck K, Ervasti JM, Snook JB, Campbell KP. Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. The Journal of cell biology. 1991;112(1):135–48. pmid:1986002; PubMed Central PMCID: PMC2288808.
  56. 56. Yoshida M, Ozawa E. Glycoprotein complex anchoring dystrophin to sarcolemma. Journal of biochemistry. 1990;108(5):748–52. pmid:2081733.
  57. 57. Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis KA, Lowe DA, Ervasti JM. Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med. 2009;6(5):e1000083. Epub 2009/05/30. pmid:19478831; PubMed Central PMCID: PMC2680620.
  58. 58. Call JA, Ervasti JM, Lowe DA. TAT-muUtrophin mitigates the pathophysiology of dystrophin and utrophin double-knockout mice. J Appl Physiol (1985). 2011;111(1):200–5. Epub 2011/05/14. pmid:21565990; PubMed Central PMCID: PMC3137527.
  59. 59. Kennedy TL, Guiraud S, Edwards B, Squire S, Moir L, Babbs A, et al. Micro-utrophin Improves Cardiac and Skeletal Muscle Function of Severely Affected D2/mdx Mice. Mol Ther Methods Clin Dev. 2018;11:92–105. Epub 2018/11/13. pmid:30417024; PubMed Central PMCID: PMC6216100.
  60. 60. Khurana TS, Watkins SC, Chafey P, Chelly J, Tome FM, Fardeau M, et al. Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscular disorders: NMD. 1991;1(3):185–94. Epub 1991/01/01. pmid:1822793.
  61. 61. Pons F, Nicholson LV, Robert A, Voit T, Leger JJ. Dystrophin and dystrophin-related protein (utrophin) distribution in normal and dystrophin-deficient skeletal muscles. Neuromuscular disorders: NMD. 1993;3(5–6):507–14. Epub 1993/09/01. pmid:8186702.
  62. 62. Helliwell TR, Man NT, Morris GE, Davies KE. The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromuscular disorders: NMD. 1992;2(3):177–84. Epub 1992/01/01. pmid:1483043.
  63. 63. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, et al. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8(3):253–61. pmid:11875496.
  64. 64. Lai Y, Zhao J, Yue Y, Wasala NB, Duan D. Partial restoration of cardiac function with DeltaPDZ nNOS in aged mdx model of Duchenne cardiomyopathy. Hum Mol Genet. 2014;23(12):3189–99. Epub 2014/01/28. [pii]. pmid:24463882; PubMed Central PMCID: PMC4030774.
  65. 65. Crawford GE, Faulkner JA, Crosbie RH, Campbell KP, Froehner SC, Chamberlain JS. Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. The Journal of cell biology. 2000;150(6):1399–410. pmid:10995444; PubMed Central PMCID: PMC2150715.
  66. 66. Gregorevic P, Blankinship MJ, Chamberlain JS. Viral vectors for gene transfer to striated muscle. Curr Opin Mol Ther. 2004;6(5):491–8. pmid:15537050.
  67. 67. Chakkalakal JV, Stocksley MA, Harrison MA, Angus LM, Deschenes-Furry J, St-Pierre S, et al. Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc Natl Acad Sci U S A. 2003;100(13):7791–6. pmid:12808150.
  68. 68. Ljubicic V, Miura P, Burt M, Boudreault L, Khogali S, Lunde JA, et al. Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Human molecular genetics. 2011;20(17):3478–93. pmid:21659335.
  69. 69. Selsby JT, Morine KJ, Pendrak K, Barton ER, Sweeney HL. Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PLoS One. 2012;7(1):e30063. pmid:22253880; PubMed Central PMCID: PMC3256197.
  70. 70. Weir AP, Morgan JE, Davies KE. A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. Neuromuscul Disord. 2004;14(1):19–23. pmid:14659408.
  71. 71. Banks GB, Combs AC, Odom GL, Bloch RJ, Chamberlain JS. Muscle structure influences utrophin expression in mdx mice. PLoS Genet. 2014;10(6):e1004431. Epub 2014/06/13. [pii]. pmid:24922526; PubMed Central PMCID: PMC4055409.
  72. 72. Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6–28 months old. J Physiol. 2001;535(Pt 2):591–600. pmid:11533147.
  73. 73. Banks GB, Gregorevic P, Allen JM, Finn EE, Chamberlain JS. Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Human molecular genetics. 2007;16(17):2105–13. Epub 2007/06/26. ddm158 [pii] pmid:17588958.
  74. 74. Faber RM, Hall JK, Chamberlain JS, Banks GB. Myofiber branching rather than myofiber hyperplasia contributes to muscle hypertrophy in mdx mice. Skelet Muscle. 2014;4:10. Epub 2014/06/10. [pii]. pmid:24910770; PubMed Central PMCID: PMC4047439.
  75. 75. Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, et al. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Mol Ther. 2007;15(2):320–9. pmid:17235310.
  76. 76. Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, et al. Modular flexibility of dystrophin: Implications for gene therapy of Duchenne muscular dystrophy. Nat Med. 2002;8(3):253–61. pmid:11875496.
  77. 77. Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020. Epub 2020/06/17. pmid:32539076; PubMed Central PMCID: PMC7296461.
  78. 78. Ramos JN, Hollinger K, Bengtsson NE, Allen JM, Hauschka SD, Chamberlain JS. Development of Novel Micro-dystrophins with Enhanced Functionality. Mol Ther. 2019;27(3):623–35. Epub 2019/02/06. pmid:30718090; PubMed Central PMCID: PMC6403485.
  79. 79. Porter GA, Dmytrenko GM, Winkelmann JC, Bloch RJ. Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle. The Journal of cell biology. 1992;117(5):997–1005. pmid:1577872; PubMed Central PMCID: PMC2289490.
  80. 80. Williams MW, Resneck WG, Bloch RJ. Membrane skeleton of innervated and denervated fast- and slow-twitch muscle. Muscle & nerve. 2000;23(4):590–9. pmid:10716771.
  81. 81. Straub V, Bittner RE, Leger JJ, Voit T. Direct visualization of the dystrophin network on skeletal muscle fiber membrane. J Cell Biol. 1992;119(5):1183–91. pmid:1447296.
  82. 82. Ehmer S, Herrmann R, Bittner R, Voit T. Spatial distribution of beta-spectrin in normal and dystrophic human skeletal muscle. Acta neuropathologica. 1997;94(3):240–6. pmid:9292693.
  83. 83. Rybakova IN, Patel JR, Ervasti JM. The dystrophin complex forms a mechanically strong link between the sarcolemma and costameric actin. J Cell Biol. 2000;150(5):1209–14. pmid:10974007.
  84. 84. Williams MW, Bloch RJ. Extensive but coordinated reorganization of the membrane skeleton in myofibers of dystrophic (mdx) mice. The Journal of cell biology. 1999;144(6):1259–70. pmid:10087268; PubMed Central PMCID: PMC2150591.
  85. 85. Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Mol Ther. 2008;16(4):657–64. pmid:18334986; PubMed Central PMCID: PMC2650831.
  86. 86. Harper SQ, Crawford RW, DelloRusso C, Chamberlain JS. Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable. Hum Mol Genet. 2002;11(16):1807–15. pmid:12140183.
  87. 87. Lai Y, Zhao J, Yue Y, Duan D. alpha2 and alpha3 helices of dystrophin R16 and R17 frame a microdomain in the alpha1 helix of dystrophin R17 for neuronal NOS binding. Proceedings of the National Academy of Sciences of the United States of America. 2013;110(2):525–30. pmid:23185009; PubMed Central PMCID: PMC3545791.
  88. 88. Infante JP, Huszagh VA. Mechanisms of resistance to pathogenesis in muscular dystrophies. Molecular and cellular biochemistry. 1999;195(1–2):155–67. pmid:10395079.
  89. 89. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002;82(2):291–329. pmid:11917091.
  90. 90. Gramolini AO, Karpati G, Jasmin BJ. Discordant expression of utrophin and its transcript in human and mouse skeletal muscles. Journal of neuropathology and experimental neurology. 1999;58(3):235–44. pmid:10197815.
  91. 91. Weir AP, Burton EA, Harrod G, Davies KE. A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. The Journal of biological chemistry. 2002;277(47):45285–90. pmid:12235137.
  92. 92. Adams ME, Anderson KN, Froehner SC. The alpha-syntrophin PH and PDZ domains scaffold acetylcholine receptors, utrophin, and neuronal nitric oxide synthase at the neuromuscular junction. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2010;30(33):11004–10. pmid:20720107; PubMed Central PMCID: PMC2936458.
  93. 93. Miyagoe-Suzuki Y, Takeda SI. Association of neuronal nitric oxide synthase (nNOS) with alpha1-syntrophin at the sarcolemma. Microscopy research and technique. 2001;55(3):164–70. pmid:11747091.
  94. 94. Yoshida M, Hama H, Ishikawa-Sakurai M, Imamura M, Mizuno Y, Araishi K, et al. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Human molecular genetics. 2000;9(7):1033–40. pmid:10767327.
  95. 95. Sanes JR, Lichtman JW. Development of the vertebrate neuromuscular junction. Annual review of neuroscience. 1999;22:389–442. Epub 1999/04/15. pmid:10202544.
  96. 96. Banks GB, Fuhrer C, Adams ME, Froehner SC. The postsynaptic submembrane machinery at the neuromuscular junction: requirement for rapsyn and the utrophin/dystrophin-associated complex. J Neurocytol. 2003;32(5–8):709–26. pmid:15034263.
  97. 97. Slater CR. Structural determinants of the reliability of synaptic transmission at the vertebrate neuromuscular junction. Journal of neurocytology. 2003;32(5–8):505–22. Epub 2004/03/23. pmid:15034250.
  98. 98. Wood SJ, Slater CR. The contribution of postsynaptic folds to the safety factor for neuromuscular transmission in rat fast- and slow-twitch muscles. The Journal of physiology. 1997;500 (Pt 1):165–76. Epub 1997/04/01. pmid:9097941; PubMed Central PMCID: PMC1159367.
  99. 99. Hennig R, Lomo T. Firing patterns of motor units in normal rats. Nature. 1985;314(6007):164–6. Epub 1985/03/14. pmid:3974720.
  100. 100. Sealock R, Butler MH, Kramarcy NR, Gao KX, Murnane AA, Douville K, et al. Localization of dystrophin relative to acetylcholine receptor domains in electric tissue and adult and cultured skeletal muscle. The Journal of cell biology. 1991;113(5):1133–44. Epub 1991/06/01. pmid:2040646; PubMed Central PMCID: PMC2289019.
  101. 101. Bailey SJ, Stocksley MA, Buckel A, Young C, Slater CR. Voltage-gated sodium channels and ankyrinG occupy a different postsynaptic domain from acetylcholine receptors from an early stage of neuromuscular junction maturation in rats. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2003;23(6):2102–11. Epub 2003/03/27. pmid:12657669.
  102. 102. Carlson CG, Roshek DM. Adult dystrophic (mdx) endplates exhibit reduced quantal size and enhanced quantal variation. Pflugers Archiv: European journal of physiology. 2001;442(3):369–75. Epub 2001/08/04. pmid:11484767.
  103. 103. Deconinck AE, Potter AC, Tinsley JM, Wood SJ, Vater R, Young C, et al. Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice. The Journal of cell biology. 1997;136(4):883–94. Epub 1997/02/24. pmid:9049253; PubMed Central PMCID: PMC2132499.
  104. 104. Banks GB, Combs AC, Chamberlain JS. Sequencing protocols to genotype mdx, mdx(4cv), and mdx(5cv) mice. Muscle & nerve. 2010;42(2):268–70. Epub 2010/06/15. pmid:20544945.
  105. 105. Gregorevic P, Meznarich NA, Blankinship MJ, Crawford RW, Chamberlain JS. Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. Muscle & nerve. 2008;37(1):104–6. Epub 2007/08/11. pmid:17691104; PubMed Central PMCID: PMC2788960.
  106. 106. Gubern C, Hurtado O, Rodriguez R, Morales JR, Romera VG, Moro MA, et al. Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC molecular biology. 2009;10:57. Epub 2009/06/18. pmid:19531214; PubMed Central PMCID: PMC2706836.
  107. 107. Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Mol Ther. 2011;19(1):36–45. pmid:20859263; PubMed Central PMCID: PMC3017440.